Here are the 10-K annual reports from electroCore, Inc. (ECOR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ECOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ECOR filings page.
electroCore, Inc. is a bioelectronic technology company focused on non-invasive neuromodulation devices and wellness products. Its main commercial offerings are the prescription gammaCore vagus nerve stimulation system for primary headaches and Quell Fibromyalgia for chronic pain, plus Truvaga and TAC-STIM wellness devices.
The company relies heavily on government and health-system customers: U.S. Department of Veterans Affairs facilities generated 71.2% of 2025 revenue, and U.K. NHS sales under the MedTech Funding Mandate added 4.4%. As of March 13, 2026, 8,083,558 common shares were outstanding and the June 30, 2025 non‑affiliate equity market value was $27,950,688.
electroCore highlights the need for additional capital, concentration of revenue in a few large customers, ecommerce and pricing risks, regulatory and reimbursement uncertainty in the U.S. and U.K., cybersecurity and FTC compliance exposure, a material weakness in internal controls, and Nasdaq listing and debt covenant risks.